SOURCE: Serenex, Inc.

May 03, 2007 09:00 ET

Serenex Announces Participation at the 2007 BIO Business Forum

DURHAM, NC -- (MARKET WIRE) -- May 3, 2007 -- Serenex, Inc., an integrated oncology-focused drug discovery and development company, announced today that Dr. Richard Kent, chief executive officer, is scheduled to present at the BIO Business Forum taking place at the 2007 BIO International Convention at the Boston Convention & Exhibition Center.

On May 8 at 11:45 a.m., Dr. Kent will give a corporate presentation at the 2007 BIO Business Forum in room C. During the presentation Dr. Kent will provide an overview of the company including recent progress, strategy, and ongoing development programs.

A replay of the presentation will be available under the "News" section of the Serenex website (www.serenex.com) approximately 12 hours after the presentation for a period of 90 days.

About Serenex

Serenex is an integrated oncology-focused drug discovery and development company. Serenex's lead program, SNX-1012, a product for chemotherapy and radiation-induced oral mucositis in solid tumor patients, is scheduled to complete phase 2 clinical trials at the end of 2007. Oral mucositis, which represents a large and underserved market, frequently causes clinicians to interrupt therapy which directly leads to decreased rates of efficacy. Additionally, Serenex has a novel small molecule inhibitor of Heat Shock Protein 90 (Hsp90) which is scheduled to begin clinical trials in the second quarter of 2007. Hsp90 is a central protein responsible for chaperoning a large number of oncogenic proteins (such as Her2 and Raf) that are necessary to support cancer cell survival and growth. Serenex's pipeline is powered by a proprietary high throughput screening platform which enables the company to profile compounds, en masse, against thousands of important therapeutic and toxicity targets. Website: www.serenex.com.

Contact Information

  • CONTACT:
    Ian Howes
    CFO & Sr. V.P. Corporate Development, Serenex, Inc.
    919/281-6001
    Email Contact

    Michelle Linn
    Linnden Communications
    508/419-1555
    Email Contact